ACT-1 A multicenter exploratory phase II study of neoadjuvant bevacizumab for newly diagnosed glioblastoma. 2024. 5. 5. v1-v1
Toshihide Tanaka, Jun Takei, Hikaru Sasaki. Response to correspondence on an exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma. Journal of Neuro-Oncology. 2024
Jun Takei, Miku Maeda, Nei Fukasawa, Masaharu Kawashima, Misayo Miyake, Kyoichi Tomoto, Shohei Nawate, Akihiko Teshigawara, Tomoya Suzuki, Yohei Yamamoto, et al. Comparative analyses of immune cells and alpha-smooth muscle actin-positive cells under the immunological microenvironment between with and without dense fibrosis in primary central nervous system lymphoma. Brain Tumor Pathology. 2024
Michiyasu Fuga, Toshihiro Ishibashi, Ken Aoki, Naoki Kato, Issei Kan, Shunsuke Hataoka, Gota Nagayama, Tohru Sano, Toshihide Tanaka, Yuichi Murayama. Intermediate catheter use is associated with intraprocedural rupture during coil embolization of ruptured intracranial aneurysms: a retrospective propensity score-matched study. Frontiers in neurology. 2024. 15. 1401378-1401378
Teshigawara A, Fuga M, Tanaka T, Tachi R, Horiuchi K, Ishibashi T, Hasegawa Y, Murayama Y. TIPS and technical nuances of digital illustration in neurointerventional surgery. World Neurosurgery. 2024
Toshihide Tanaka, Ryota Tamura, Jun Takei, Yohei Yamamoto, Yasuharu Akasaki, Yuichi Murayama, Keisuke Miyake, Hikaru Sasaki. AB052. A multicenter prospective exploratory phase II study of neoadjuvant bevacizumab for newly diagnosed malignant glioma. Chinese Clinical Oncology. 2024
TOSHIHIDE TANAKA, RYOTA TAMURA, JUN TAKEI, YUKINA MORIMOTO, AKIHIKO TESHIGAWARA, KYOICHI TOHMOTO, YUKI KURANARI, RYOTARO IMAI, YOHEI YAMAMOTO, YUZURU HASEGAWA, et al. ACT-1 A multicenter exploratory phase II study of neoadjuvant bevacizumab for newly diagnosed malignant glioma ~ The second report. Neuro-Oncology Advances. 2023. 5. v1-v2
COT-4 Comparative volumetric analyses following bevacizumab therapy for a patient with co-incidence of glioblastoma, meningioma, and dural arteriovenous fistula. 2023. 5. 5. v3-v3
ANGI-1 Regulation of alternative angiogenic factors in bevacizumab therapy for glioblastoma. 2023. 5. 5. v1-v2
IMT-1 A role of dendritic cell immunotherapy as a modality in multidisciplinary therapy for glioblastoma. 2023. 5. 5. v3-v4
A multicenter prospective exploratory phase II study of neoadjuvant bevacizumab for newly diagnosed malignant glioma
(The 19th Asian Society for Neuro-Oncology Annual Meeting 2024)
An exploratory multi-institutional prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed and recurrent glioblastoma.
(4th Global Experts Meeting on FIN (Frontier in Neuroscience) 2024 2024)
Impact of neoadjuvant bevacizumab on neuroradiographical response and histological findings related to tumor microenvironment in newly diagnosed and recurrent glioblastomas.
(Tissue Engineering and Regenerative Medicine 2024 2024)